Catalent

Catalent Net Debt per Share

Delisted

The Net Debt per Share of Catalent (CTLT) as of Nov 5, 2026 is 25.50 USD. In the previous year, Net Debt per Share was 25.24 USD — a change of 1.03% (higher).

Net Debt per Share

25.50USD

YoY

1.03%

Last updated:

Net Debt per Share of Catalent is 2024 25.50 USD. Net Debt per Share of Catalent was 2023 25.24 USD. It decreases by 1.03% higher compared to the previous year.

The Catalent Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
9.90 USD
Jan 1, 2018
12.77 USD
Jan 1, 2019
14.44 USD
Jan 1, 2020
11.41 USD
Jan 1, 2021
12.56 USD
Jan 1, 2022
20.24 USD
Jan 1, 2023
25.24 USD
Jan 1, 2024
25.50 USD
The Catalent Net Debt per Share history
YEARNet Debt per ShareYoY
25.50USD+1.03%
25.24USD+24.70%
20.24USD+61.13%
12.56USD+10.13%
11.41USD-21.00%
14.44USD+13.10%
12.77USD+28.97%
9.90USD+3.60%
9.55USD-0.02%
9.56USD-34.40%
14.57USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Catalent Stock analysis

What does Catalent do? Catalent Inc is a global leader in advanced active ingredients and medical products, as well as solutions for drug development and manufacturing. The company was founded in 1933 by the Schering brothers in the USA and has become one of the preferred partners in the pharmaceutical industry due to its innovation, flexibility, and reliability. Catalent's business model is based on providing high-quality services and products that contribute to improving human health. The company offers a wide range of solutions, from active ingredient development to drug formulation and manufacturing, clinical trials, and product packaging. Through this comprehensive offering, Catalent helps its customers accelerate their drug development and product launch. The company is divided into different business sectors with specialized solutions, including the manufacturing of biopharmaceuticals such as antibodies, cell therapies, and vaccines, as well as medical devices, active ingredient manufacturing, and pharmaceutical development and manufacturing. Catalent's services also include active ingredient development, assisting customers in all stages of drug development from identifying new active ingredients to optimizing production processes. The company specializes in formulating drugs into suitable delivery forms that ensure safe and effective use, offering a variety of oral, inhalable, and parenteral formulations. Catalent also provides clinical trials, testing the efficacy and safety of drugs in clinical trials. The company has state-of-the-art facilities and expertise to professionally and successfully support its customers in conducting clinical studies. Additionally, Catalent offers a wide range of packaging solutions, including glass bottles, plastic containers, aluminum tubes, and the finishing and packaging of finished drugs. The company has advanced production systems that enable quick and flexible packaging production in any desired size and shape. Overall, Catalent provides its customers with a comprehensive range of services and products that enable fast and effective drug development and market launch. The company's strong innovation and diverse range of expertise make it a preferred partner in the pharmaceutical industry. Catalent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Catalent stock

Net Debt per Share of Catalent is 25.50 USD in 2024.

Net Debt per Share of Catalent changed from 25.24 USD to 25.50 USD, representing a 1.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Catalent since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Catalent

All Key Metrics — Catalent